Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?


Creative Commons License

El-Khouly F. E., van Zanten S. E. M. V., Santa-Maria Lopez V., Hendrikse N. H., Kaspers G. J. L., Loizos G., ...More

JOURNAL OF NEURO-ONCOLOGY, vol.145, no.1, pp.177-184, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 145 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1007/s11060-019-03287-9
  • Journal Name: JOURNAL OF NEURO-ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.177-184
  • Keywords: Diffuse intrinsic pontine glioma (DIPG), Diffuse midline glioma H3-K27 mutant (DMG K3-27M), Chemotherapy, Radiotherapy, BRAIN-STEM GLIOMA, CHILDREN, COHORT, PROGNOSIS, TUMORS
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University Affiliated: Yes

Abstract

Introduction Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is to evaluate the current tendency for its treatment in Europe in order to develop (inter)national consensus guidelines.